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To the Editor:
Pulmonary pleomorphic carci-
noma (PPC) is an uncommon tumor and 
accounts for 0.1% to 0.4% of all lung 
cancer.1 Because of the infrequency, 
there are no data on the optimal treatment 
of unresectable PPC. In this letter, we 
would like to describe our experience of 
a patient with an advanced PPC harbor-
ing anaplastic lymphoma kinase (ALK) 
rearrangement treated by crizotinib.
A 50-year-old man presented with 
productive cough and back pain. He did 
not smoke or have a significant medical 
history. Computed tomography revealed 
the left hilar lymphadenopathy, masses 
involving the left lung and the right ret-
roperitoneal space, and multiple bone 
lesions. High uptake on fluorodeoxyglu-
cose positron emission tomography was 
seen in these abnormalities. Magnetic 
resonance imaging of the head pre-
sented normal. In transbronchial biopsy 
specimens, sarcomatoid spindle cells and 
polygonal epithelioid cells proliferated 
without distinct architectural features. 
Immunohistochemistry demonstrated 
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FIGURE 1.  Posttreatment changes of computed tomography findings. A, Arrows 
show the tumor after one cycle of first-line chemotherapy. B, Tumor shrank a 
month after crizotinib initiation.
positive for pancytokeratin and vimen-
tin and negative for thyroid transcription 
factor-1 and other mesenchymal mark-
ers, such as S-100, desmin, bcl-2, and 
CD34. Thus, the disease was a carcinoma 
with a sarcomatoid component, resulting 
in the diagnosis of PPC. He received pal-
liative radiotherapy for bone metasta-
ses and systemic chemotherapy with a 
regimen of gemcitabine and cisplatin a 
month after the first presentation. After 
one cycle, his general condition deterio-
rated and computed tomography revealed 
disease progression (Fig. 1A). Then, we 
detected ALK rearrangement by immu-
nohistochemistry and break-apart fluo-
rescent in situ hybridization and started 
subsequent therapy with crizotinib 
(500 mg daily). He achieved a partial 
response by 1 month (Fig. 1B); however, 
crizotinib was discontinued 3 months 
after initiation because of new liver and 
brain metastases. He was pronounced 
dead soon. Autopsy was performed and 
we confirmed the diagnosis of PPC.
PPC is a rare malignant epithe-
lial tumor that contains carcinomatous 
and sarcomatoid components. It is an 
aggressive tumor, and patients with 
advanced stage usually have a poor 
prognosis. Palliative chemotherapy 
commonly used for non–-small-cell 
lung cancer is ineffective2 and novel 
approaches are required.
During the last decade, knowl-
edge about oncogenic mutations 
affecting proliferation of lung cancer 
cells has accumulated enough for the 
development of targeted treatments. 
Especially, epidermal growth fac-
tor receptor (EGFR) and ALK testing 
is recommended for all lung cancers 
with an adenocarcinoma component. 
Nonetheless, gene alterations suitable 
for targeted therapy are poorly known 
in PPC issues. The prevalence of EGFR 
mutations (20%) and the poor response 
to the EGFR tyrosine kinase inhibitor 
were previously reported in the analy-
sis of 17 patients.3 The data on ALK 
rearrangement are almost nonexistent. 
To the best of our knowledge, this is 
the first report of ALK-rearranged 
advanced PPC treated by crizotinib.
Crizotinib showed marked antitu-
mor activities for ALK-rearranged non–
-small-cell lung cancer with a median 
progression-free survival of 7.7 months 
in the salvage setting.4 The present case 
obtained the response to crizotinib, but 
it was transient. Recently, Kobayashi 
et al5 described a patient with ALK-
rearranged lung adenocarcinoma who 
acquired resistance to crizotinib caused 
by sarcomatoid transformation. These 
findings implied that ALK-rearranged 
PPC has poor sensitivity to crizotinib.
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MET Mutation 
Associated with 
Responsiveness to 
Crizotinib
To the Editor:
Activation of c-MET oncogene 
can be the result of amplification or 
activating mutations. In this letter, 
we would like to share our experience 
of treating a patient with metastatic 
lung adenocarcinoma, whose tumor 
was found to harbor a MET mutation 
occurring at a splice site within the 
juxtamembrane domain.
A 71-year-old Caucasian man 
with a 15 pack-year smoking history 
presented to our clinic with a biopsy-
proven left lung adenocarcinoma 
with a 6.4 × 5 cm left pleural-based 
mass invading the fourth rib, left hilar 
lymphadenopathy, and numerous bilat-
eral sub-centimeter pulmonary nod-
ules. He received palliative thoracic 
radiation to a total dose of 3000 cGy, 
followed by two cycles of chemother-
apy with carboplatin AUC 5 and peme-
trexed 500 mg/m2 intravenously every 
3 weeks. Follow-up computed tomog-
raphy scan of the chest and abdomen 
revealed improvement in the previously 
irradiated left lung mass, mediasti-
nal and hilar adenopathy, but new and 
enlarging pulmonary nodules, bilateral 
supraclavicular adenopathy and new 
sclerotic bone lesions.
Ta rg e t e d   n e x t - g e n e r a t i o n 
 sequencing of 42 cancer-related genes 
(Comprehensive Cancer Gene Set ver-
sion 2 assay, GPS@WUSTL, St. Louis, 
MO) was performed on DNA derived 
from the formalin-fixed paraffin-
embedded tumor biopsy specimen.1 
A MET single nucleotide variant was 
identified, chr7:g.116412043G>C, 
involving the terminal nucleotide of 
exon 14 (Fig. 1). This variant could 
result in a p.D1028H missense muta-
tion (NM_001127500:c.3082G>C), 
but is also predicted by in-silico mod-
eling to affect the splice donor site 
(Fig. 2). Fluorescence in-situ hybrid-
ization analysis was performed using 
commercial probes (Abbott Molecular, 
Des Plaines, IL) for MET/CEP7 
(7q31.2/7p11.1-q11.1). Polysomy of 
chromosome 7 was noted (CEP7 and 
MET average copy numbers 2.31 and 
2.23, respectively), although the MET/
CEP7 ratio of 0.96 was negative for 
MET amplification. He was started on 
crizotinib 250 mg orally twice daily. 
Restaging computed tomography 
scans after 6 weeks of therapy revealed 
decrease in size of the pulmonary 
lesions with continued response at 6 
months (Fig. 3).
The MET receptor tyrosine 
kinase is a known oncogene, with a 
somatic mutation frequency of 8.3% 
in lung adenocarcinoma and 2% in 
lung squamous cell carcinoma, based 
on sequencing data from The Cancer 
Genome Atlas (TCGA).2 MET muta-
tions are seen typically in smok-
ers, and may co-occur with TP53 
mutations.3 Unlike activating EGFR 
mutations that occur primarily in 
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the tyrosine kinase domain, MET 
mutations are distributed across all 
domains of the gene. Although muta-
tions in the semaphorin domain may 
affect ligand-binding affinity, juxta-
membrane domain mutations impact 
CBL-mediated ubiquitination and 
MET receptor degradation. Somatic 
splice site mutations involving MET 
exon 14, resulting in deletion of the 
juxtamembrane domain, have been 
described in lung cancer.4,5 The juxta-
membrane domain contains a binding 
site for CBL, which is required for 
ubiquitin-mediated MET degrada-
tion. The variant described here could 
result in over-activation of MET via 
skipping of exon 14 with loss of the 
CBL/ubiquitin-mediated degradation 
(Fig. 2). To the best of our knowledge, 
this is the first report demonstrating 
successful targeting of this MET tyro-
sine kinase variant by crizotinib.
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